GLP-1 Biology Pioneer; Distinguished Professor, Indiana University
Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, where he served as chairman of the Chemistry Department. Dr. DiMarchi is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. He is former decade-long chairman of the Peptide Therapeutics Foundation and is recognized as an international spokesperson for macromolecular medicines. Since 2003, he has co-founded six successful biotech companies: Ambrx, Marcadia, Calibrium, MB2, Assembly and MBX BioSciences.